Zhao Liuyang, Yu Na, Guo Tianfang, Hou Yixuan, Zeng Zongyue, Yang Xiaorong, Hu Ping, Tang Xi, Wang Jian, Liu Manran
Authors' Affiliations: Key Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education; and Experimental Teaching Center of Basic Medicine Science, Chongqing Medical University, Chongqing, China.
Authors' Affiliations: Key Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education; and Experimental Teaching Center of Basic Medicine Science, Chongqing Medical University, Chongqing, ChinaAuthors' Affiliations: Key Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education; and Experimental Teaching Center of Basic Medicine Science, Chongqing Medical University, Chongqing, China.
Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):1047-54. doi: 10.1158/1055-9965.EPI-13-0696. Epub 2014 Mar 17.
Although numerous investigators have made efforts to assess prognostic biomarkers of prostate cancer, no biomarker has been recommended for clinical practice.
According to REMARK (Reporting recommendations for tumor marker prognostic studies) and MISFISHIE (Minimum information specification for in situ hybridization and immunohistochemistry experiments) guidelines, the published articles of immunohistochemistry-based prognostic biomarkers on prostate cancer were extracted and pooled.
Ninety-three prognostic biomarkers from 92 high-quality cohort studies were included in this meta-analysis. Our analysis reveals some promising independent prognostic biomarkers, including Ki-67 [all-cause mortality (ACM) HR, 1.85; 95% confidence interval (CI), 1.06-3.25; PSM HR, 1.82; 95% CI, 1.42-2.34; DFS HR, 1.51; 95% CI, 1.31-1.75]; Bcl-2 (ACM HR, 2.14; 95% CI, 1.27-3.58; PSM HR, 1.61; 95% CI, 1.01-2.57; DFS HR, 3.86; 95% CI, 2.14-6.96); CD147 (ACM HR, 2.63; 95% CI, 1.19-5.81; DFS HR, 5.84; 95% CI, 3.41-9.99); COX-2 (PSM HR, 7.6; 95% CI, 0.7-80.1; DFS HR, 7.9; 95% CI, 2.62-23.83); ALDH1A1 (ACM HR, 1.73; 95% CI, 1.163-2.527; PSM HR, 1.05; 95% CI, 1.028-1.107), and FVIII (ACM HR, 1.76; 95% CI, 1.19-2.60; PSM HR, 1.01; 95% CI, 1.01-1.02).
Our analysis identified a subset of biomarkers (Ki-67, Bcl-2, CD147, COX-2, ALDH1A1, and FVIII) that may have prognostic value for predicting the outcome of patients with prostate cancer.
These reliable prognostic biomarkers will improve the clinical management of patients with prostate cancer. Cancer Epidemiol Biomarkers Prev; 23(6); 1047-54. ©2014 AACR.
尽管众多研究人员努力评估前列腺癌的预后生物标志物，但尚无生物标志物被推荐用于临床实践。
根据REMARK（肿瘤标志物预后研究报告建议）和MISFISHIE（原位杂交和免疫组化实验的最小信息规范）指南，提取并汇总已发表的基于免疫组化的前列腺癌预后生物标志物文章。
本荟萃分析纳入了来自92项高质量队列研究的93种预后生物标志物。我们的分析揭示了一些有前景的独立预后生物标志物，包括Ki-67[全因死亡率（ACM）风险比（HR），1.85；95%置信区间（CI），1.06 - 3.25；倾向评分匹配（PSM）HR，1.82；95%CI，1.42 - 2.34；无病生存期（DFS）HR，1.51；95%CI，1.3I - 1.75]；Bcl-2（ACM HR，2.14；95%CI，1.27 - 3.58；PSM HR，1.61；95%CI，1.01 - 2.57；DFS HR，3.86；95%CI，2.14 - 6.96）；CD147（ACM HR，2.63；95%CI，1.19 - 5.81；DFS HR，5.84；95%CI，3.41 - 9.99）；COX-2（PSM HR，7.6；95%CI，0.7 - 80.1；DFS HR，7.9；95%CI，2.62 - 23.83）；ALDH1A1（ACM HR，1.73；95%CI，1.163 - 2.527；PSM HR，1.05；95%CI，1.028 - 1.107），以及FVIII（ACM HR，1.76；95%CI，1.19 - 2.60；PSM HR，1.01；95%CI，1.01 - 1.02）。
我们的分析确定了一组生物标志物（Ki-67、Bcl-2、CD147、COX-2、ALDH1A1和FVIII），它们可能对预测前列腺癌患者的预后具有价值。
这些可靠的预后生物标志物将改善前列腺癌患者的临床管理。《癌症流行病学、生物标志物与预防》；23(6)；1047 - 54。©2014美国癌症研究协会。
